Analyst consensus rating
Revelation Biosciences Analyst Rating: none
REVB is rated none by 2 analysts with a $17.75 target. As of 2026-08-26.
Direct answer
Revelation Biosciences's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.75.
Forecast evidence checked August 26, 2026.
Get free Revelation Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.00
- Average price target
- $17.75
- High price target
- $19.50
- Low price target
- $16.00
- Low target gap
- +1,500%
- Target upside
- +1,675%
- High target gap
- +1,850%
- Target range width
- 350%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Revelation Biosciences?
Revelation Biosciences has a verified none consensus. The same dataset has an average price target of $17.75.
How far are Revelation Biosciences's low and high targets from the recorded price?
The low target implies +1,500%, while the high target implies +1,850%.
How many analysts are included in Revelation Biosciences's consensus?
The verified consensus includes 2 analysts.
How is Revelation Biosciences's target upside or downside calculated?
The average target of $17.75 is divided by the recorded price of $1.00, then one is subtracted to produce +1,675%. This does not guarantee a future return.
When was Revelation Biosciences's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.